secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200673
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts
--------------------------------------------------------------------------------

- Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).
- Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).
- FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.
- Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.
- G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/0001193125-24-200673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/d886471d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer